跳至主要内容
临床试验/NCT01468493
NCT01468493Unknown不适用

A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis

Guangdong Provincial People's Hospital1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
90
试验地点
1
主要终点
serum suPAR level when proteinuria reduction >=50% or complete remission

研究概览

简要总结

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
14 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at entry is between 14 and 70 years
  • biopsy-proven primary FSGS
  • proteinuria >=3 g/day
  • without corticosteroids or CsA treatment before entry

排除标准

  • Chronic Inflammatory Diseases
  • malignant tumor
  • diabetes mellitus
  • contraindications for the treatment of corticosteroids or CsA treatment
  • untolerate to or unwilling to accept corticosteroids or CsA treatment

结局指标

主要结局

serum suPAR level when proteinuria reduction >=50% or complete remission

时间窗: 6 months after steriod alone or CsA plus steriod treatment

serum suPAR level when proteinuria reduction of \>=50% or complete remission occurs within \<=6 months of steroid alone or CsA plus steroid treatment

次要结局

  • serum suPAR level after 6 months of steroid or CsA treatment without remission(6 months after steroid alone or CsA plus steroid treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wei Shi

Director of renal division of Guangdong General Hospital

Guangdong Provincial People's Hospital

研究点 (1)

Loading locations...

相似试验